Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Patients With Active Rheumatoid Arthritis Who Have Previously Had an Inadequate Response to One or More TNF Antagonist Therapies

NCT00603525 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00603525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00603525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Patients With Active Rheumatoid Arthritis Who Have Previously Had an Inadequate Response to One or More TNF Antagonist Therapies
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2008
Completion date
July 31, 2013
Enrollment
169 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid